Glenmark Pharmaceuticals gets USFDA’s approval for Clindamycin Phosphate Foam

21 Sep 2021 Evaluate

Glenmark Pharmaceuticals has received final approval by the United States Food & Drug Administration (USFDA) for Clindamycin Phosphate Foam, 1%, the generic version of Evoclin Foam, 1%, of Mylan Pharmaceuticals Inc. According to IQVIA sales data for the 12 month period ending July 2021, the Evoclin Foam, 1%, market achieved annual sales of approximately $12.0 million.

Glenmark’s current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 47 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

1992.70 -8.35 (-0.42%)
28-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1610.15
Dr. Reddys Lab 1224.30
Cipla 1328.25
Zydus Lifesciences 896.60
Lupin 2121.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×